RecruitingPhase 2Phase 3NCT04787471

Corneal Crosslinking for Treatment of Corneal Neovascularization

Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and/or Infection

Sponsor

Price Vision Group

Enrollment

62 participants

Start Date

May 3, 2021

Study Type

INTERVENTIONAL

Conditions

Corneal Neovascularization

Summary

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying 10 minute photoactivation of riboflavin 0.1% and 30 minute photoactivation of riboflavin 0.1% for people with corneal neovascularization. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCT30 minute photoactivation of riboflavin 0.1%

Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes

COMBINATION_PRODUCT10 minute photoactivation of riboflavin 0.1%

Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes

Locations(1)

Price Vision Group

Indianapolis, Indiana, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04787471

Related Trials

Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.

NCT073296861 location